# Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

> **NCT04666259** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 56 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia - Chronic Phase

## Interventions

- **DRUG:** ABL001

## Key facts

- **NCT ID:** NCT04666259
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-25
- **Primary completion:** 2023-06-20
- **Final completion:** 2024-06-26
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04666259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04666259, "Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04666259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*